Search Articles — Sudonull

https://sudonull.com/mitmproxy-in-ui-autotests-traffic-management-for-qa

Practical guide to integrating mitmproxy into UI autotests for intercepting and modifying network traffic. Python code examples.

https://sudonull.com/api-testing-checklist-and-autotests

Full API Testing Checklist: Status Codes, Structure, Boundaries, auth. Postman, Jest+axios Examples, AI Automation. For QA and Developers — Implement a Systematic Approach.

https://sudonull.com/fixtures-in-go-for-autotests-practice-with-axiom

How to extract infrastructure from Go tests using fixtures and the Axiom library. Clean, maintainable integration tests without code duplication.

https://sudonull.com/ai-agents-for-qa-11-pipeline-skills

Multi-agent system automates 80% QA: from requirements decomposition to autotests in GitLab. Architecture, skills, integrations for middle/senior QA. Study the implementation on Claude Code Skills.

https://sudonull.com/qa-and-a-b-testing-courses-top-5-in-2026

Review of 5 software testing courses with practice on Yandex services, AI autotests, and A/B simulators. Comparison of formats, prices, pros/cons. Choose according to level and tasks — start QA training.

https://ymaho.com/anifrolumab-in-autoinjector-fda-approves-home-treatment-for-lupus

FDA approves Saphnelo Pen for home treatment of lupus. Learn how the anifrolumab autoinjector is changing therapy and reducing access barriers. Details and forecasts.

https://ymaho.com/universal-car-t-therapy-fda-allows-trials-for-autoimmune-diseases

FDA approved clinical trials of allogeneic CAR-T cell therapy QT-019C for lupus and scleroderma. Savings up to $100 billion, no chemotherapy. Learn about the breakthrough.

https://ymaho.com/imp761-first-lag-3-agonist-passes-phase-i-in-autoimmune-diseases

Analysis of IMP761 data from Immutep at EULAR 2026: a new class of drugs for treating rheumatoid arthritis without total immunosuppression. Safety, mechanism, and prospects. Read more.

https://ymaho.com/lag-3-agonist-imp761-first-clinical-success-in-autoimmune-diseases

LAG-3 agonist IMP761 has shown clinical efficacy in suppressing T-cells for the first time. Learn about the revolution in treating autoimmune diseases without side effects. Read more.

https://ymaho.com/enspryng-reduced-the-risk-of-relapses-in-mogad-by-68

Genentech proved the efficacy of satralizumab in a rare autoimmune disease. The risk of attacks decreased by 68%, new lesions by 79%. Learn how the first targeted drug fills the niche of empirical therapy.

https://ymaho.com/fda-approved-first-gene-therapy-for-lad-i-in-children

FDA approved Kresladi (marnetegragene autotemcel) — the first stem cell gene therapy for children with severe LAD-I. Learn about the mechanism, precedents, and business model. Detailed analysis on the website.

https://ymaho.com/car-t-therapy-for-lupus-100-remission-in-a-small-cohort

German rheumatologists achieved 100% remission in lupus with CAR-T. Four-year data, immune reset mechanism, and forecasts. Read.

https://ymaho.com/tzield-approved-for-children-from-1-year-delaying-type-1-diabetes

FDA expanded indications for teplizumab to children from one year. First drug capable of delaying diabetes for years at the preclinical stage. Learn how infusions change the prognosis for infants.

https://ymaho.com/saphnelo-pen-approved-by-fda-treating-lupus-at-home

FDA approved Saphnelo subcutaneous pre-filled pens for lupus treatment. Patients can self-administer the drug without visiting a clinic. Learn about the breakthrough in therapy.

https://ymaho.com/car-t-therapy-for-lupus-fda-approval-2026

Analysis of FDA approval of the first CAR-T cell therapy for severe lupus. Key players, forecasts, and hidden risks. Find out who is leading the race.